The purpose of this study was to describe biologics and biosimilars use, dispensing patterns, indication history of patients exposed to biologics and biosimilars, and coding patterns in the Sentinel Distributed Database (SDD). The medications of interest were the biologic Neupogen, its biosimilars Granix, Zarxio, Nivestym, the biologic Neulasta, its biosimilar Fulphila, and the biologic Remicade and its biosimilars Inflectra and Renflexis. This study consists of two reports.
- Report 1: This report describes the indication history of patients exposed to biologics and biosimilars for filgrastim, pegfilgrastim, and infliximab; uptake of these drugs over time; and coding patterns of these drugs in claims data in the SDD.
- Report 2: This report describes biologics and biosimilars use and dispensing patterns among all patients in the SDD.
The study period for Report 1 includes data from January 1, 2015 to August 31, 2018. The study period for Report 2 includes data from January 1, 2015 to August 21, 2018. We distributed this request to 17 Sentinel Data Partners on March 15, 2019.